Cancer Pain Management Market Report by Treatment (Immunotherapy, Radiotherapy, Chemotherapy, Hormone Therapy, Targeted Therapies, Inhibitors, Surgery, Others), Drug Type (Opioids, Non-Opioids, Nerve Blockers), Disease Indication (Lung Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Blood Cancer, Others), Country and Company Analysis 2023-2030
Global Cancer Pain Management Market Outlook
Global Cancer Pain Management Market is predicted to hit over US$ 7.80 Billion by 2030 according to Renub Research. Pain is a common and dreaded symptom experienced by individuals undergoing cancer treatment and long-term cancer survivors. Cancer pain can result from the disease itself, its treatments, or a combination of both and it may be acute or chronic, with some individuals experiencing pain long after treatment has ended. The number of people living with cancer-related pain is on the rise, due to the increasing number of long-term cancer survivors and the growing prevalence of cancer in older populations worldwide. With advances in cancer treatments, people are now living longer with advanced cancer, further contributing to the growing number of individuals with cancer-related pain.
The growing incidence of cancer-related pain and the effects of the opioid epidemic on the management of chronic pain have renewed efforts to develop new pain medications that are not addictive, as well as non-drug therapies for managing chronic pain. There is increasing recognition of the need for greater accessibility to pain management medications, which is driving the consumption and acceptance of these drugs over other therapeutic options. Consequently, the high levels of awareness, ease of access, fast-acting nature, and cost-effectiveness of pain management medications have made them a preferred choice over other therapy options.
Cancer Pain Management Market is expanding growth at a CAGR of 5.25% during the forecast period 2022 to 2030
Despite the existing treatment options, the cancer pain management industry is constantly looking for newer and more effective ways to manage pain in cancer patients. Key manufacturers in the industry are exploring the use of the network model for research and development to come up with innovative treatment options. Ongoing research and development efforts help businesses analyze new treatment combinations and their effectiveness in pain management. There is a shift in the industry towards developing personalized drugs, biologics, and quick-dose lifestyle medicines, which make up over 70% of the medications currently in development. The focus is no longer solely on managing symptoms, but on amending the disease itself. Manufacturers are also moving away from chemical-based medications and towards biologic products-based therapeutics. Sympathetic administrative reform is also helping to facilitate the development of novel and effective pain management medications. The Cancer Pain Management Market is valued at US$ 5.18 Billion in the year 2022.
Targeted Therapies is Fastest growing segment in the Cancer Pain Management Industry
By Treatment, Cancer Pain Management Market is divided into Inhibitors, Surgery Immunotherapy, Radiotherapy, Hormone Therapy, Chemotherapy, Targeted Therapies, and Others. Targeted therapies are an important and rapidly evolving field in cancer treatment, and they may play a significant role in managing pain associated with cancer. Targeted therapies are medications that are specifically designed to target the molecular pathways involved in the growth and spread of cancer cells.
By inhibiting the activity of certain proteins or molecules that promote cancer cell growth, targeted therapies can help to reduce the size of tumors and slow down their growth. The advantage of these therapies is that they typically spare normal cells from damage. Targeted therapies may also be used in combination with other treatments, such as chemotherapy, radiation therapy, or surgery, to manage pain associated with cancer. The development of new targeted therapies is an active area of research within the cancer pain management industry, with the aim of improving outcomes and quality of life for cancer patients.
Opioids Reported Foremost Market Stake in 2023
By Drug Type, Cancer Pain Management Market is sub-divided into Opioids, Non-Opioids and Nerve Blockers. Opioids drug are a category of medications frequently utilized to manage pain in cancer patients. These drugs operate by binding to particular receptors in the brain and spinal cord, which can alleviate pain. Opioids are effective for treating both short-term and long-term pain, and they can be administered in various forms, including tablets, patches, and injections.
However, their use should be approached with caution and personalized to each patient's unique requirements and situation, as opioids have potential risks and side effects. Healthcare providers should collaborate closely with their patients to design a thorough pain management strategy that evaluates the advantages and disadvantages of all possible options. Despite their risks, opioids continue to play a vital role in the cancer pain management industry.
Lung Cancer is projected to dominate the Disease Indication segment of Pain Management Market Revenue
By Disease Indication, Cancer Pain Management Market is classified into Lung Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Blood Cancer and Others. The lung cancer segment was the leading disease indication in the cancer pain market and is predicted to maintain its dominance throughout the forecast period. This is attributed to the rising incidence of lung cancer, high prevalence of pain associated with lung cancer, and the availability of effective cancer pain analgesics for treating lung cancer. However, the breast cancer segment is anticipated to experience significant market growth during the forecast period, owing to the increasing prevalence of breast cancer and greater adoption of pain analgesics in breast cancer treatment.
United States of America is estimated to have the Largest Market Share for Cancer Pain Management Market
By Country, Cancer Pain Management Market is break up into 10 major markets: United States, United Kingdom, Japan, France, Germany, Italy, Spain, Saudi Arabia, China and Korea. The cancer pain management industry in the United States is a crucial component of the global market. It is among the largest markets for cancer pain management worldwide, propelled by various factors such as the high incidence of cancer in the nation, increased awareness about the significance of pain management in cancer treatment, and access to advanced medical technologies and therapies. Furthermore, the market is reinforced by a well-established healthcare infrastructure, reimbursement policies, and government initiatives to enhance cancer care and pain management.
This industry is also highly dynamic, with a constant evolution of novel drugs and therapies, and has enormous growth potential in the upcoming years. As the importance of pain management in cancer care continues to gain recognition, and new drugs and therapies are developed, the United States cancer pain management market is poised for significant expansion.
Key Player Analysis
There are several leading competitors contending in Cancer pain management 10MM market. Some of the notable players in the industry include Daiichi Sankyo Co., Ltd., Hisamitsu Pharmaceutical Co., Inc., Orexo AB, Pfizer Inc, Teva Pharmaceutical Industries Limited, Sanofi, Johnson & Johnson and Eli Lilly.
Renub Research latest report “Cancer Pain Management 10MM Industry, Forecast By Treatment (Immunotherapy, Radiotherapy, Chemotherapy, Hormone Therapy, Targeted Therapies, Inhibitors, Surgery, Others), Drug Type (Opioids, Non-Opioids, Nerve Blockers), Disease Indication (Lung Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Blood Cancer, Others), Country (United States, United Kingdom, Japan, France, Germany, Italy, Spain, Saudi Arabia, China, Korea), Companies (Daiichi Sankyo Co., Ltd., Hisamitsu Pharmaceutical Co., Inc., Orexo AB, Pfizer Inc, Teva Pharmaceutical Industries Limited, Sanofi, Johnson & Johnson, Eli Lilly)” provides a detailed analysis of Cancer Pain Management 10MM Industry.
Treatment – Market has been covered from 8 viewpoints:
1. Immunotherapy
2. Radiotherapy
3. Chemotherapy
4. Hormone Therapy
5. Targeted Therapies
6. Inhibitors
7. Surgery
8. Others
Drug Type – Market has been covered from 3 viewpoints:
1. Opioids
2. Non-Opioids
3. Nerve Blockers
Disease Indication – Market has been covered from 6 viewpoints:
1. Lung Cancer
2. Colorectal Cancer
3. Breast Cancer
4. Prostate Cancer
5. Blood Cancer
6. Others
Country – Market has been covered from 10 viewpoints:
1. United States
2. United Kingdom
3. Japan
4. France
5. Germany
6. Italy
7. Spain
8. Saudi Arabia
9. China
10. Korea
Company Insights:
• Overview
• Recent Development
• Financial Insight
Companies Covered:
1. Daiichi Sankyo Co., Ltd.
2. Hisamitsu Pharmaceutical Co., Inc.
3. Orexo AB
4. Pfizer Inc
5. Teva Pharmaceutical Industries Limited
6. Sanofi
7. Johnson & Johnson
8. Eli Lilly
Report Details:
| Report Features | Details |
| Base Year | 2022 |
| Historical Period | 2018 - 2022 |
| Forecast Period | 2023 - 2030 |
| Market | US$ Billion |
| Segment Covered | Treatment , Drug Types, Disease Indication, and Countries |
| Countries Covered | United States, United Kingdom, Japan, France, Germany, Italy, Spain, Saudi Arabia, China, and Korea |
| Companies Covered | Daiichi Sankyo Co., Ltd., Hisamitsu Pharmaceutical Co., Inc., Orexo AB, Pfizer Inc, Teva Pharmaceutical Industries Limited, Sanofi, Johnson & Johnson, and Eli Lilly |
| Customization Scope | 20% Free Customization |
| Post-Sale Analyst Support | 1 Year (52 Weeks) |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on request) |
1. Introduction
2. Research & Methodology
3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. SWOT Analysis - Cancer Pain Management Market
5.1 Strength
5.2 Weakness
5.3 Opportunity
5.4 Threat
6. Porter’s Five Forces
6.1 Bargaining Power of Buyers
6.2 Bargaining Power of Suppliers
6.3 Degree of Competition
6.4 Threat of New Entrants
6.5 Threat of Substitutes
7. Disease Background and Overview
7.1 Introduction
7.2 Etiology and Types
7.3 Cancer Pain Classification Systems
7.3.1 International Association for the Study of Pain (IASP) Taxonomy
7.3.2 ICD-11
7.3.3 Edmonton Classification System for Cancer Pain (ECS-CP)
7.4 Cancer Pain Pathophysiology
7.5 Cancer Pain Syndromes
7.6 Clinical Presentation and Assessment of Pain
8. Treatment and Management
8.1 NCCN Guidelines
8.2 ESMO Clinical Practice Guidelines (2018)
8.3 Spanish Guidelines
8.4 Canadian Recommendations for the Management of Breakthrough Cancer Pain (BTCP)
8.5 Multimodal Personalized Management of Cancer Pain
9. Cancer Pain Management Market – 10 Major Markets
10. Cancer Pain Epidemiology and Patient Population
10.1 Cancer Patients - 10 MM
10.2 Cancer Patients by Type, 2020 - 10 MM
10.3 Cancer Patients by Gender - 10 MM
10.4 Cancer Patients by Mortality Rate – 10 MM
11. Market Share Analysis - Global Cancer Pain Management
11.1 By Treatment
11.2 By Drug Type
11.3 By Disease Indication
11.4 By Country
12. Treatment - Global Cancer Pain Management 10MM
12.1 Immunotherapy
12.2 Radiotherapy
12.3 Chemotherapy
12.4 Hormone Therapy
12.5 Targeted Therapies
12.6 Inhibitors
12.7 Surgery
12.8 Others
13. Drug Type – Global Cancer Pain Management 10 MM
13.1 Opioids
13.2 Non-Opioids
13.3 Nerve Blockers
14. Disease Indication – Global Cancer Pain Management 10 MM
14.1 Lung Cancer
14.2 Colorectal Cancer
14.3 Breast Cancer
14.4 Prostate Cancer
14.5 Blood Cancer
14.6 Others
15. Country – Global Cancer Pain Management 10 MM
15.1 United States
15.1.1 By Cancer Incidence - Per Lakh of Total Population
15.1.2 By Gender - Cancer Patients
15.1.2.1 Male
15.1.2.2 Female
15.1.3 By Type – Cancer Patients, 2020
15.1.4 By Mortality - Cancer Patients
15.1.5 By Price Analysis – Cancer Pain Management Drug Price Per Capita
15.1.6 Market Analysis
15.2 United Kingdom
15.2.1 By Cancer Incidence - Per Lakh of Total Population
15.2.2 By Gender - Cancer Patients
15.2.2.1 Male
15.2.2.2 Female
15.2.3 By Type – Cancer Patients, 2020
15.2.4 By Mortality - Cancer Patients
15.2.5 By Price Analysis – Cancer Pain Management Drug Price Per Capita
15.2.6 Market Analysis
15.3 Japan
15.3.1 By Cancer Incidence - Per Lakh of Total Population
15.3.2 By Gender - Cancer Patients
15.3.2.1 Male
15.3.2.2 Female
15.3.3 By Type – Cancer Patients, 2020
15.3.4 By Mortality - Cancer Patients
15.3.5 By Price Analysis – Cancer Pain Management Drug Price Per Capita
15.3.6 Market Analysis
15.4 France
15.4.1 By Cancer Incidence - Per Lakh of Total Population
15.4.2 By Gender - Cancer Patients
15.4.2.1 Male
15.4.2.2 Female
15.4.3 By Type – Cancer Patients, 2020
15.4.4 By Mortality - Cancer Patients
15.4.5 By Price Analysis – Cancer Pain Management Drug Price Per Capita
15.4.6 Market Analysis
15.5 Germany
15.5.1 By Cancer Incidence - Per Lakh of Total Population
15.5.2 By Gender - Cancer Patients
15.5.2.1 Male
15.5.2.2 Female
15.5.3 By Type – Cancer Patients, 2020
15.5.4 By Mortality - Cancer Patients
15.5.5 By Price Analysis – Cancer Pain Management Drug Price Per Capita
15.5.6 Market Analysis
15.6 Italy
15.6.1 By Cancer Incidence - Per Lakh of Total Population
15.6.2 By Gender - Cancer Patients
15.6.2.1 Male
15.6.2.2 Female
15.6.3 By Type – Cancer Patients, 2020
15.6.4 By Mortality - Cancer Patients
15.6.5 By Price Analysis – Cancer Pain Management Drug Price Per Capita
15.6.6 Market Analysis
15.7 Spain
15.7.1 By Cancer Incidence - Per Lakh of Total Population
15.7.2 By Gender - Cancer Patients
15.7.2.1 Male
15.7.2.2 Female
15.7.3 By Type – Cancer Patients, 2020
15.7.4 By Mortality - Cancer Patients
15.7.5 By Price Analysis – Cancer Pain Management Drug Price Per Capita
15.7.6 Market Analysis
15.8 Saudi Arabia
15.8.1 By Cancer Incidence - Per Lakh of Total Population
15.8.2 By Gender - Cancer Patients
15.8.2.1 Male
15.8.2.2 Female
15.8.3 By Type – Cancer Patients, 2020
15.8.4 By Mortality - Cancer Patients
15.8.5 By Price Analysis – Cancer Pain Management Drug Price Per Capita
15.8.6 Market Analysis
15.9 China
15.9.1 By Cancer Incidence - Per Lakh of Total Population
15.9.2 By Gender - Cancer Patients
15.9.2.1 Male
15.9.2.2 Female
15.9.3 By Type – Cancer Patients, 2020
15.9.4 By Mortality - Cancer Patients
15.9.5 By Price Analysis – Cancer Pain Management Drug Price Per Capita
15.9.6 Market Analysis
15.10 Korea
15.10.1 By Cancer Incidence - Per Lakh of Total Population
15.10.2 By Gender - Cancer Patients
15.10.2.1 Male
15.10.2.2 Female
15.10.3 By Type – Cancer Patients, 2020
15.10.4 By Mortality - Cancer Patients
15.10.5 By Price Analysis – Cancer Pain Management Drug Price Per Capita
15.10.6 Market Analysis
16. Emerging Therapies
16.1 Key Cross Competition
16.2 Tetrodotoxin: WexPharma
16.2.1 Product description
16.2.2 Other developmental activities
16.2.3 Clinical development
16.2.4 Safety and efficacy
16.3 Resiniferatoxin: Sorrento Therapeutics
16.3.1 Product description
16.3.2 Other developmental activities
16.3.3 Clinical development
16.3.4 Safety and efficacy
16.4 QIXLEEF: Tetra Bio-Pharma
16.4.1 Product description
16.4.2 Other developmental activities
16.4.3 Clinical development
16.4.4 Safety and efficacy
17. Company Analysis
17.1 Daiichi Sankyo Co., Ltd.
17.1.1 Overview
17.1.2 Business Strategy
17.1.3 Financial Insight
17.2 Hisamitsu Pharmaceutical Co., Inc.
17.2.1 Overview
17.2.2 Business Strategy
17.2.3 Financial Insight
17.3 Orexo AB
17.3.1 Overview
17.3.2 Business Strategy
17.3.3 Financial Insight
17.4 Pfizer Inc
17.4.1 Overview
17.4.2 Business Strategy
17.4.3 Financial Insight
17.5 Teva Pharmaceutical Industries Limited
17.5.1 Overview
17.5.2 Business Strategy
17.5.3 Financial Insight
17.6 Sanofi
17.6.1 Overview
17.6.2 Business Strategy
17.6.3 Financial Insight
17.7 Johnson & Johnson
17.7.1 Overview
17.7.2 Business Strategy
17.7.3 Financial Insight
17.8 Eli Lilly
17.8.1 Overview
17.8.2 Business Strategy
17.8.3 Financial Insight
Reach out to us
Call us on
USA: +1-678-302-0700
INDIA: +91-120-421-9822
Drop us an email at
info@renub.com